Lario Therapeutics wins $2.4M funding to advance CNS drug platform
Lario Therapeutics received $2.4M from The Michael J. Fox Foundation and Wellcome to expand its Cav1.3 neuronal calcium channel platform for CNS disorders, including Parkinson's; the funding will support preclinical research and cross-disorder exploration toward future clinical programmes.
Why it mattersThe $2.4M award from MJFF and Wellcome will fund Cav1.3 preclinical studies, accelerating Parkinson's candidates toward clinical trials.